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This study was performed to quantify the fraction of
excreted creatinine not attributable to creatinine filtration
for accurately determining the glomerular filtration rate
in mice. To measure this we compared creatinine filtration
with the simultaneous measurement of inulin clearance using
both single-bolus fluorescein isothiocyanate (FITC)-inulin
elimination kinetics and standard FITC-inulin infusion.
During anesthesia, creatinine filtration was found to be
systematically higher than inulin clearance in both male
and female C57BL/6J mice. The secretion fraction was
significantly less in female mice. Administration of either
cimetidine or para-aminohippuric acid, competitors of
organic cation and anion transport respectively, significantly
reduced the secretion fraction in male and female mice
and both significantly increased the plasma creatinine level.
Creatinine secretion in both genders was not mediated by
the organic cation transporters OCT1 or OCT 2 since secretion
fraction levels were identical in FVB wild-type and OCT1/2
knockout mice. Thus, secretion accounts for about 50
and 35% of excreted creatinine in male and female mice,
respectively. Increasing plasma creatinine threefold by
infusion further increased the secretion fraction. Renal
organic anion transporter 1 mRNA expression was higher
in male than in female mice, reflecting the gender difference
in creatinine secretion. Hence we show that there is
a major secretory contribution to creatinine excretion
mediated through the organic anion transport system.
This feature adds to problems associated with measuring
endogenous creatinine filtration in mice.
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Endogenous creatinine clearance (Ccr), usually by 24-h urine
collection and a single plasma determination, is a practical way
to measure glomerular filtration rate (GFR) and it is therefore
widely used to assess this important indicator of renal function.
The option of genetic manipulation in mice and the need of
phenotypic evaluation of ‘new’ animal models have led to an
increased use of the Ccr in this species for measurement of
GFR. Nevertheless, there are well-recognized problems asso-
ciated with the use of this technique necessitating careful
validation for the intended use. Creatinine secretion is one of
the known complications of this technique, as it causes
overestimation of the real GFR to various extent.1 Because it
suppresses creatinine secretion, cimetidine has been used
successfully to increase the accuracy of GFR estimation.2–4
The contribution of secretion to the excretion of creatinine has
not been systematically studied in mice. Furthermore, previous
evidence suggesting gender differences in creatinine secretion
raises the question whether sex is a determinant of Ccr in mice.
The present experiments were performed to establish the
magnitude of the secretory creatinine component in two widely
used mouse strains (C57BL6/J and FVB), and to investigate
which organic transport system mediates creatinine secretion.
Our data indicate that creatinine secretion contributes
significantly to urinary creatinine excretion, and that the
secretory component can be reduced by para-aminohippuric
acid (PAH) and cimetidine, competitive inhibitors of organic
anion and cation transporters, respectively. In view of earlier
evidence with expressed organic cation transporters (OCTs), it
was unexpected that absence of the organic cation transporters
OCT1 and OCT2 did not affect creatinine secretion. As the
renal expression of OCT3 is extremely low, our results suggest a
major role for organic anion transporter (OAT)-mediated
transport despite the fact that creatinine at physiological pH is
a base. OAT1-mediated creatinine uptake could explain the
higher rates of creatinine secretion in male than female mice, as
OAT1 is expressed in the kidney with male preponderance.
RESULTS
FITC-inulin plasma decay versus Ccr
Fluorescein isothiocyanate (FITC)-inulin clearance (Cin) of
C57BL/6J wild-type (WT) male mice derived from plasma
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decay after bolus injection averaged 248±29 ml/min, a value
significantly lower than the simultaneously measured en-
dogenous Ccr of 370±32 ml/min (Po0.05; n¼ 11). The
secreted fraction of creatinine estimated from the Ccr versus
Cin averaged 0.32±0.06.
FITC-inulin steady-state infusion clearance versus
endogenous Ccr
Simultaneous measurements of creatinine and steady-state
FITC-Cin are summarized in Figures 1–3. In male C57BL/6J
mice (Figure 1), Ccr averaged 508±98 ml/min compared with
a Cin of 215±34 ml/min (n¼ 8; Po0.05) yielding a secretion
fraction (SFcr) of 0.56±0.02. In female mice, Ccr was
601±38 ml/min, and Cin was 328±21 ml/min (n¼ 8;
Po0.05). The SFcr was 0.44±0.04, significantly lower than
those observed in the male mice (n¼ 8; Po0.05). Likewise in
FVB WT mice (Figures 2 and 3), Ccr exceeded Cin in both
male (758±76 vs 345±16 ml/min; n¼ 9; Po0.05) and
female mice (657±55 vs 424±15 ml/min; n¼ 12; Po0.05),
leading to a significantly higher SFcr in male than female mice
(0.59±0.05 vs 0.33±0.04; Po0.05).
Effect of PAH
Para-aminohippuric acid was used to determine whether the
OAT system participates in the secretion of creatinine. There
were no differences in age, body weight (BW), kidney weight,
mean arterial blood pressure (MAP), and heart rate between
FVB mice before or during PAH administration, but urine
flow increased during PAH infusion (Table 1). While Ccr
remained higher than Cin, the clearance difference was
reduced in both male FVB WT mice (Ccr: 553±70 ml/min,
Cin: 364±44 ml/min; n¼ 5; Po0.05) and female FVB WT
mice (Ccr: 418±26 ml/min, Cin: 338±30 ml/min; n¼ 5;
Po0.05; see Figure 1). Calculated SFcr was significantly
reduced by PAH from 0.59 to 0.34±0.03 (Po0.05) in male
mice, and from 0.33 to 0.19±0.05 (Po0.05) in female mice.
The reduction of creatinine secretion was accompanied by a
significant increase in plasma creatinine concentration in
PAH-treated mice (Figure 4a) from 0.083±0.006 (n¼ 21) to
0.232±0.029mg/dl (n¼ 10; Po0.05) at time point P1
(B45min after treatment started).
Effect of cimetidine
To determine whether the secretion of creatinine is mediated
by the organic cation transport system, we compared Ccr and
Cin during intravenous application of the histamine
2-receptor antagonist cimetidine in male and female
C57BL/6J mice. Age, BW, kidney weight, MAP, and heart
rate were comparable in C57BL/6J mice without or with
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Figure 1 | Inulin and creatinine clearances in male and female
C57BL/6J mice: effect of cimetidine. Left: Comparison between
the clearances of inulin and creatinine in male (a; n¼ 8) and
female (b; n¼ 8) C57BL/6J mice without (closed symbols)
and with cimetidine-treatment (open symbols). Lines connect
simultaneous clearance measurements from individual animals;
horizontal bars indicate mean values. Right: Secretion fractions
calculated from the difference between creatinine and inulin
clearances as indicated in Materials and Methods section.
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Figure 2 |Measurements of the clearances of inulin (Cin) and
creatinine (Ccr) in FVB wild-type mice without (closed
symbols) and during PAH administration (open symbols).
(a) Male mice under control conditions (n¼ 9) and during PAH
administration (n¼ 5) and calculated SFcr (bars on the right).
(b) Female mice without treatment (n¼ 12) and with PAH treatment
(n¼ 5) and calculated SFcr (bars on the right). Lines connect
simultaneous clearance measurements from individual animals
and horizontal bars are mean values.
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cimetidine treatment (Table 1). Our results show that Ccr
remained higher than Cin, but that the clearance difference
was significantly reduced in both male mice (Ccr: 364±39 ml/
min, Cin: 234±23 ml/min; n¼ 6; Po0.05) and female mice
(Ccr: 373±29 ml/min, Cin: 286±20 ml/min; n¼ 6; Po0.05;
see Figure 1). Cimetidine reduced the SFcr in male mice from
0.56 to 0.34±0.07 (Po0.05) and in female mice from 0.44 to
0.23±0.03 (Po0.05). Plasma creatinine concentration in
mice after receiving cimetidine forB45min (time point P1)
was 0.173±0.020mg/dl (n¼ 12), significantly higher than
the mean value of 0.113±0.007mg/dl (n¼ 16) in control
mice (Po0.05; Figure 4b).
Creatinine secretion in FVB WT and OCT1/2 / mice
In an attempt to assess the role of OCT1 and/or OCT2 in
creatinine secretion, we compared Ccr and Cin in mice with a
null mutation in OCT1 and OCT2 expression (Figure 4).
OCT1/2 / mice were comparable with WT FVB mice in
age, BW, kidney weight, MAP, and heart rate (Table 1). In
male OCT1/2-deficient mice, Ccr averaged 793±49 ml/min,
and this was significantly higher than the Cin of 312±20 ml/
min (n¼ 8; Po0.05). Similarly, Ccr exceeded Cin in female
OCT1/2 / mice (677±74 vs 411±20 ml/min; n¼ 7;
Po0.05). SFcr was 0.60±0.03 in male mice and 0.37±0.05
in female mice, and these values were not significantly different
from those obtained in FVB WT animals. Plasma creatinine
concentrations were not different between OCT1/2 / and
WT animals (OCT1/2 /: 0.102±0.013mg/dl, n¼ 15; WT:
0.083±0.006mg/dl, n¼ 21; Figure 5c).
Exogenous Ccr
To determine creatinine secretory capacity, we measured
FITC-inulin and Ccr in male CD1 mice after elevating plasma
creatinine by infusion over a concentration range that might
result from a decline of renal function. The results are
summarized in Figure 5. It can be seen that increasing plasma
creatinine from 0.265±0.03mg/dl over 0.69±0.15mg/dl to
8.1±1.55mg/dl was followed by a linear increase in filtered
creatinine (FITC-inulin Pcr) as expected. Secreted creati-
nine (excreted – filtered creatinine) also increased markedly
in a way best described by a linear regression line, although at
the highest concentration a deviation from this line seems to
become evident. Secreted creatinine as percent of excreted
creatinine showed a value of 52.7±2.8% at a plasma
concentration of 0.265mg/dl and a value of 68.9±6.1% at
a plasma concentration of 0.692mg/dl (P¼ 0.054).
Organic ion transporter mRNA expression
Expression levels of organic ion transporters were determined
in FVB WT mice to identify gender differences similar to
those seen in the functional studies. Of the three OATs tested
(Figure 6a), only the renal expression of OAT1 was lower in
female relative to male mice (29±2%; n¼ 12; Po0.05). In
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Figure 3 |Comparison between the clearances of inulin and
creatinine in FVB wild-type and Oct1/2 /mice. (a) Inulin and
creatinine clearances in male WT (closed symbols; n¼ 9) and
OCT1/2 / mice (open symbols; n¼ 8) and calculated secretion
fractions (bars on the right). (b) Inulin and creatinine clearances in
female WT (closed symbols; n¼ 12) and OCT1/2 / mice (open
symbols; n¼ 7) and calculated secretion fractions (bars on the
right). Lines connect simultaneous clearance measurements from
individual animals and horizontal bars are mean values.
Table 1 | Summary of age, weight, blood pressure, and heart rate in control and cimetidine-treated C57BL/6J mice, and in FVB
WT, FVB WT PAH-treated, and OCT1/2 / mice
C57BL/6J +Cimetidine FVB WT +PAH OCT1/2 /
N 16 12 21 10 15
Age (months) 4.0±0.2 5.2±0.5 3.7±0.1 6.3±0.7 2.3±0.0
Body weight (g) 25.8±0.6 25.3±1.0 26.5±0.9 27.5±1.6 23.1±0.7
Kidney weight (g) 0.29±0.01 0.28±0.02 0.33±0.02 0.35±0.03 0.29±0.02
Urine flow (ml/min) 1.32±0.16 1.55±0.14 1.59±0.15 11.0±1.44 1.6±0.20
MAP (mmHg) 74±2 71±3 96±3 90±4 83±3
Heart rate (b.p.m.) 490±26 473±36 406±10 423±7 402±12
Abbreviations: FITC, fluorescein isothiocyanate; MAP, mean arterial blood pressure; OCT, organic cation transporter; PAH, para-aminohippuric acid; WT, wild-type.
MAP and heart rate were obtained following surgical preparation but before starting FITC-inulin infusion.
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contrast, expression of both OAT2 and OAT3 was higher in
female than in male mice.
We also determined OCT3 expression to assess whether
this transporter may be upregulated in OCT1/2 / mice.
Consistent with earlier observations OCT3 mRNA was found
to be only minimally expressed in the kidney of WT mice in
comparison with OCT1 and OCT2 (Figure 6b). Expression
levels of OCT3 increased in the OCT1/2 / mice in both
male and female animals (Figure 6c). Immunoblots with an
antibody against OCT3 showed a relative expression
(arbitrary densitometric units) of 0.91±0.14 in WT (n¼ 4)
and of 1.29±0.09 in OCT1/2 / mice (n¼ 4; P¼ 0.07).
Similarly, OAT1 protein expression was found to be
comparable averaging in relative densitometric units
1.18±0.1 in WT and 1.31±0.27 in OCT1/2/ mice
(n¼ 4; not significant).
DISCUSSION
In this report, we used simultaneous determinations of Cin
and endogenous Ccr in mice to quantify the fraction of
excreted creatinine not attributable to filtration. The main
finding is that the endogenous Ccr exceeds the Cin by a factor
of approximately two, indicating that about half of creatinine
excretion is derived from tubular secretion. The unusually
large secretory component adds to the list of problems
associated with the use of the endogenous Ccr in mice. The
high creatinine secretion most likely contributes to the low
plasma creatinine levels generally found in mice.
The validity of FITC-inulin as a marker for GFR in mice
has been established previously by showing identity of
simultaneously measured FITC-inulin and iothalamate
clearances.5 As plasma values of creatinine are overestimated
when using the Jaffe colorimetric method, all creatinine
measurements in this study were performed by an high-
performance liquid chromatography (HPLC) separation
method. Endogenous Ccr determined by standard clearance
methods over 1 h exceeded FITC-Cin, whether determined by
single-injection plasma decay or urinary collection techni-
ques. The range of values suggests that 30–60% of total Ccr is
due to tubular secretion. Previous data have identified a
sexual dimorphism in creatinine transport, as the Ccr/Cin
ratio was observed to be higher in male than in female rats;
administration of testosterone to female rats elevated this
ratio to male values.6,7 In this study, we have confirmed a
gender difference in both C57BL/6J and FVB mouse strains,
as the difference between Ccr and Cin was consistently higher
in male than in female mice. The secreted fraction of
creatinine of male mice increased further (from about
53–69%) when plasma creatinine was increased by infusion
about threefold. A greater contribution of secretion to
excretion is typically noticed under clinical conditions when
plasma creatinine increases as a result of a decrease of GFR.
Enhanced creatinine secretion at moderate GFR reductions
delays the increase of plasma creatinine levels and adds to the
imprecision of using plasma creatinine as an index of GFR.
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Figure 4 | Effects of PAH, cimetidine, and genetic deletion of OCT1 and OCT2 on plasma creatinine concentration of FVB mice.
(a) Plasma creatinine concentrations in FVB wild-type mice without (closed symbols; n¼ 21) and with PAH treatment (open symbols;
n¼ 10); horizontal bars indicate mean values. (b) Plasma creatinine concentrations in C57BL/J wild-type mice (closed symbols; n¼ 16)
before (control) and during treatment with cimetidine; horizontal bars indicate mean values. (c) Plasma creatinine concentrations
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Further elevations of plasma creatinine in our studies were
associated with reduced SFcrs, although clear transport
saturation and attainment of a transport maximum was not
achieved.
There have been no previous reports of a similarly high
creatinine secretion in mice. Nevertheless, examination of
earlier reports suggests partial agreement with the present
findings. In female rats, a comparison between 3H-Cin and
endogenous Ccr has revealed a secretory fraction of 0.57.
8 A
SFcr of 0.25 has been found in mice during infusion of both
inulin and creatinine, an approach in which the elevated
creatinine levels may have saturated creatinine secretion; as a
consequence, the relative contribution of secretion to total
clearance may have decreased.9 Studies using the colorimetric
Jaffe reaction for plasma measurements are probably invalid
as they would systematically overestimate plasma creatinine
and therefore underestimate Ccr.
10,11 In a direct comparison
in conscious C57BL/6J mice, 24 h clearances of endogenous
creatinine and FITC-inulin administered through implanted
osmotic pumps showed a good correlation, but Ccr was
markedly higher than Cin.
10 From these data, a secretory
fraction of about 0.6–0.7 can be estimated assuming that an
incomplete urine collection would affect recovery of inulin
and creatinine to a comparable extent. In contrast, a
negligible tubular SFcr of only 0.06 was recently observed in
another study in male C57Bl/6J mice, in which 24 h
clearances of creatinine and FITC-inulin were compared.12
The reason for this is unclear, but the drastic differences
between similar studies point to unrecognized problems in
the application of 24 h clearances to mice.10,12 Although the
approach used in our study requires anesthesia and surgery,
direct urine collections from the bladder bracketed by plasma
determinations provide reliable clearance estimates for the
selected experimental conditions. Differences in results are
probably not related to the use of different mouse strains, as
in our study similarly high SFcrs were observed in C57BL/6J,
FVB, and CD1 strains.
Subsequent in vivo studies were performed to identify the
basolateral transport system responsible for creatinine
uptake. As creatinine with pKa’s of 4.8 and 9.2 is a mono-
protonated cation at physiological pH, it was expected that
uptake occurred mainly through the organic cation transport
system. Consistent with this expectation is the finding that
the calculated creatinine SFcr was markedly reduced by the
administration of the histamine 2-receptor antagonist
cimetidine, a high affinity substrate of OCT transporters.
Consistent with previous observations in humans, cimetidine
did not alter the clearance of inulin indicating that it did not
interfere with GFR and the filtered load of creatinine.2,3 Thus,
the decrease in creatinine excretion caused by cimetidine was
most certainly due to a reduction of creatinine secretion.13
Competitive inhibition of cimetidine transport by creatinine
and vice versa has been demonstrated previously.14,15
Cimetidine and creatinine have been shown to be selective
substrates for the OCT2 stably expressed in HEK 293
cells.16,17 Our data show that cimetidine reduced the
secretory fraction of creatinine by about 40% in males and
49% in females. As a consequence of reduced secretion,
plasma creatinine concentration was found to be significantly
increased about 45min after starting the cimetidine
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Figure 6 | Expression of organic anion (OAT) and organic
cation (OCT) transporter mRNA in male and female FVB mice.
(a) OAT1, OAT2, and OAT3 mRNA quantification in male (closed
bars; n¼ 9) and female FVB mice (open bars; n¼ 12); mRNA
of OAT1 from male mice was used as reference point (100%).
(b) OCT1, OCT2, and OCT3 mRNA quantification in male (closed
bars; n¼ 9) and female FVB mice (open bars; n¼ 12); mRNA of
OCT1 was set to 100%. (c) OCT3 mRNA quantification in FVB wild-
type mice (female: black open bars, n¼ 12; male: black closed bar,
n¼ 9) and OCT1/2 / mice (female: gray open bar, n¼ 7; male:
gray closed bar, n¼ 8); mRNA of FVB wild-type mice was set to 100%.
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treatment. One can estimate that with complete cessation
of creatinine secretion and distribution of the added
creatinine in the extracellular space, plasma creatinine
would reach 0.34±0.04mg/dl by 45min. As the actual
plasma concentration in the cimetidine-treated mice was
found to be about 50% lower, the increase of plasma
creatinine is consistent with a reduction of creatinine
secretion by about half.
Despite the evidence supporting a role of OCTs in
creatinine secretion, mice with deletion of both OCT1 and
OCT2 did not show detectable differences in creatinine
secretion compared with WT mice. Thus, neither OCT1 nor
OCT2 appear to be responsible for creatinine uptake into the
proximal tubule in vivo. This is consistent with absence of
measurable differences in plasma creatinine between
OCT1/2 / and control mice. OCT1 and OCT2 have been
shown to be the major cation transporters in the kidney,
while OCT3 has comparatively low renal expression
levels.18,19 Nevertheless, cimetidine has been found to
interfere with organic cation uptake in Caki-1 cells, a cell
line of human renal origin that expresses OCT3, but not
OCT2.20 There was an upregulation of OCT3 in OCT1/
OCT2-deficient mice, but expression levels remained ex-
tremely low, probably insufficient to explain normal rates of
creatinine uptake in the absence of OCT1 and OCT2. Overall,
our results imply that cimetidine may not inhibit creatinine
uptake by competing for OCT1 or OCT2 binding.
Previous observations in guinea-pigs have shown that
renal creatinine secretion is inhibited by the classical OAT
inhibitor probenecid.21 As probenecid and creatinine had
identical retention times in our HPLC system, we used the
classical organic anion substrate PAH as competitive
inhibitor of OATs. Our data show that the reduction of
creatinine secretion caused by PAH was similar to that caused
by cimetidine. The PAH-induced reduction of creatinine
secretion was also accompanied by a significant increase of
plasma creatinine. Studies in OAT1 / mice have demon-
strated that PAH is almost exclusively transported by the
OAT1.22 Thus, our data seem to support the notion that
creatinine uptake in mice is for the most part mediated by
OAT1. Indirect support for this is the higher expression of
OAT1 in male than in female mice, a gender difference that
parallels our finding of a higher creatinine secretion in males
than in females.23 An implication of this conclusion would be
that the charge of a substrate does not reliably predict
the interaction with a specific transporter. In an extensive
in vivo uptake study, Ullrich et al.24,25 have identified a large
number of ‘bisubstrates’ that can interact with both the
organic anion and organic cation transport systems. This
work confirmed in a systematic way previous evidence
showing that acidity or basicity are insufficient criteria for
predicting specific substrate/transporter interactions.26,27 Of
particular interest is the observation that the basolateral
uptake of cimetidine is additively blocked by probenecid and
tetraethylammonium, blockers of organic anion and cation
transporters, respectively.15,24,28
In conclusion, Ccr in mice is about twice as high as the Cin
indicating that about half of urinary creatinine excretion is
derived from tubular secretion. A reduction of creatinine
secretion was caused by both the organic cation cimetidine
and the organic anion PAH. Genetic deletion of OCT1 and
OCT2 did not affect creatinine secretion. Thus, at least in the
absence of OCT-mediated transport the OAT system is
mainly responsible for creatinine secretion.
MATERIALS AND METHODS
Animals
Experiments were performed in C57BL/6J mice from our own
breeding colony. Mice homozygous for targeted disruption of the
OCT genes Slc22a1 and Slc22a2 (OCT1/2/) and matched FVB
WT mice were obtained from Taconic (Hudson, NY, USA). CD-1
WT mice were purchased from Charles River Laboratories
(Wilmington, MA, USA). Animals were kept on standard rodent
chow and tap water ad libitum. Animal care and experimentation
were approved by the NIDDK Animal Care and Use Committee and
carried out in accordance with National Institutes of Health
principles as outlined in their Guide for the Care and Use of
Laboratory Animals.
Materials
Fluorescein isothiocyanate-inulin, cimetidine, PAH, HEPES, and
bovine serum albumin were purchased from Sigma-Aldrich (St
Louis, MO, USA). TheB2.5% FITC-inulin solution was prepared as
previously described29 and diluted before each experiment with
bovine serum albumin 2.25% to a concentration of 0.5% FITC-
inulin.
Animal preparation
Mice were injected with thiobutabarbital intraperitoneally (Inactin;
100mg/kg BW) and ketamine subcutaneously (100mg/kg BW), and
placed on a servo-controlled operating table to maintain core body
temperature at 38.0 1C. A tracheotomy was performed and a low
flow of 100% oxygen was directed toward the tracheal tube for the
whole duration of the experiment. Polyethylene catheters for
infusions were inserted into the right jugular vein. Another catheter
was inserted into the left femoral artery for continuous measure-
ment of MAP. Urine was collected through an implanted bladder
catheter. After the experiment, mice were killed and kidney weights
were determined.
FITC-Cin by plasma decay kinetics
A bolus of aroundB2.5% FITC-inulin (3.7 ml g BW) was injected
into the retro-orbital plexus of C57BL/6J WTmale mice, and blood
was collected at 3, 7, 10, 15, 35, 55, and 75min after injection.
Plasma fluorescence was measured as described below. To obtain the
Cin, a two phase exponential decay curve was performed and the
clearance was calculated using an FITC-inulin standard. Urine
collections for Ccr were started 2min after FITC-inulin injection and
continued for 1 h. Ccr was calculated according to the U/PV
principle for the matching plasma and urine samples.
Steady-state FITC-Cin
C57BL/6J WT, FVB WT, and FVB OCT1/2 / mice were infused
with 0.9% saline (10 ml/g/BW per h), and after the initial
measurement of MAP an infusion of 0.5% FITC-inulin was started
(0.25 ml/g/BW per min) at least 30min before the first blood
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collection. Blood was drawn through the arterial catheter three times
at 0min (P1), 30min (P2), and 60min (P3) of the measurement
period. In between the blood samples (P1–P2¼Period 1,
P2–P3¼Period 2), urine was collected in 10min intervals (U1 to
U3 and U4 to U6) and weighed for volume determination.
Cimetidine was administered as a 30mg/kg BW bolus followed by
a maintenance infusion at a rate of 10mg/kg/BW per h.30 PAH was
administered as a 100mg/kg/BW bolus followed by a maintenance
infusion at a rate of 1mg/kg/BW per min.
To assess the effect of elevating plasma creatinine levels on
creatinine secretion, exogenous creatinine (Sigma-Aldrich) was infused
at a rate of 10ml/min to deliver either 5 or 50mg/min, and clearance
measurements were started after 30min according to the steady-state
FITC-Cin protocol (see above). These studies were performed in CD1
mice to broaden the spectrum of mouse strains used in the study.
Fluorescein isothiocyanate-inulin in plasma and urine samples
was measured after adding 500mM HEPES buffer (pH 7.4) in a
ND-3300 fluorospectrometer (NanoDrop Technologies, DE, USA).
Plasma fluorescence in each urine collection interval was obtained
by linear interpolation between bracketing values, and the Cin for
each 10min interval was calculated from urine fluorescence/plasma
fluorescence  urine volume. Cin were averaged for periods 1 and 2
for statistical analysis.
Creatinine concentrations (ccr) in plasma and urine were
determined by modifying established HPLC methods described
previously,10,31 using an Agilent Technologies1100 series pump
(Agilent Technologies, Santa Clara, CA, USA) and autosampler, and
a 1200 series variable wavelength detector (wavelength 225 nm).
Column dimensions were 50 2.1mm, and 5 mm particle size
strong cation exchange resin, Zorbax SCX (Agilent Technologies)
was used. Column temperature was room temperature, and flow
rate was set at 1ml/min. The mobile phase consisted of 2 l of 5mM
sodium acetate adjusted to pH 4.2 with glacial acetic acid, 80ml of
methanol and 20ml of acetonitrile (ACN) to make a total volume of
2.1 l. The solution was filtered through 0.22mm durapore membrane
filters (Millipore, Billerica, MA, USA). All reagents were HPLC
grade or better. Creatinine was purchased from Sigma-Aldrich and
standard solutions were made up in the mobile phase. For sample
analysis, 24 ml of cold ACN that had been acidified with 1:200
(vol/vol) of glacial acetic acid was added to 6 ml of plasma/urine
to precipitate proteins (1:4 ratio of ACN to plasma). Tubes were
vortexed and kept at 4 1C for 15min followed by centrifugation at
10,000 r.p.m. for 10min in a refrigerated centrifuge. The supernatant
was transferred to a new Eppendorf tube. The ACN and any aqueous
phase were evaporated to dryness in a Speed-Vac (Thermo Savant,
Holbrook, NY, USA). The residue containing the creatinine was
resuspended in 42ml of HPLC mobile phase and transferred to an
autosampler vial. A volume of 30ml of solution was used for HPLC
analysis. The Waters Empower software (Milford, MA, USA) was used
for signal collection and calculation of sample concentration.
Creatinine clearances were calculated from Ucr/PcrV and
averaged for periods 1 and 2 and further used for statistical analysis.
To quantify the secretory component of the Ccr, SFcr was calculated from
SFcr ¼ ðCcr  CinÞ=Ccr
mRNA quantification
Total RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad,
CA, USA) from whole kidneys of FVB WT and FVB OCT1/2 /
mice. Reverse transcription was performed using SuperScript II
(Invitrogen). cDNA levels for OCT1, OCT2, OCT3, OAT1, OAT2,
and OAT3 were determined by real-time PCR using the following
primer and probe sets (Applied Biosystems, Foster City, CA,
USA): Mm00456306_m1 (Oct1, Scl22a1), Mm00457295_m1 (Oct2,
Slc22a2), Mm00488294_m1 (Oct3, Slc22a3), Mm00456258_m1
(Oat1, Slc22a6), Mm00460672_m1 (Oat2, Slc22a7), Mm00459534_m1
(Oat3, Slc22a8), and housekeeping gene Mm03024075_m1 (HPRT1,
hypoxanthine guanine phosphoribosyl transferase). All primer pairs
span an intron.
Immunoblotting
Kidneys were homogenized on ice in 500 ml of chilled 1 lysis
buffer (10 ) no. 9803 (Cell Signaling Technology, Danvers, MA,
USA) supplemented with 1mM phenylmethylsulfonyl fluoride.
Protein in the supernatant after centrifugation at 10,000 g
(30min at 4 1C) was determined by BCA Protein Assay Reagents
A no. 23223 and B no. 1859078 (Thermo Fisher Scientific, Waltham,
MA, USA). Protein (150 mg per well) mixed with sample loading
buffer was subjected to 10% SDS-polyacrylamide gel electrophoresis
gel separation and transferred to a polyvinylidene difluoride
membrane (Invitrogen) for immunoblotting. Nonspecific binding
sites on the membrane were blocked with 5% defatted milk in
phosphate-buffered saline (PBS)-T buffer (PBS with 0.1% Tween 20)
at room temperature for 1 h, followed by two washes in PBS-T.
The membranes were then incubated with rabbit anti-mouse OAT1
antibody (ABBIOTEC, LLC, CA, USA), goat anti-mouse OCT3 anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in PBS-T
buffer containing 5% bovine serum albumin overnight at 4 1C. After
five washes in PBS-T, the membranes were incubated with donkey anti-
rabbit horseradish peroxidase immunoglobulin-G (Santa Cruz Biotech-
nolgy), donkey anti-goat horseradish peroxidase immunoglobulin-G
(Santa Cruz Biotechnology) for detection of OAT1 and OCT3,
respectively. Immunoreactive bands were then detected by enhanced
chemiluminescence. The membrane was stripped with stripping buffer
(Thermo Fisher Scientific), and re-blotted with actin antibody (Sigma-
Aldrich). The densities of specific bands were quantified by Image J.
Statistics
GraphPad Prism (version 3.0, La Jolla, CA, USA) was used for all
statistical analyses. A dependent or independent t-test was used for
comparison of data values. A P-value of equal or less than 0.05 was
considered to indicate significant differences. All averages are
expressed as arithmetic mean±s.e.m.
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